Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21650124 | 0.90 | CTSS (0.50) | CTSKCTSSSCN9ASYKATM | |
| SCHEMBL9963895 | 0.90 | CTSS (0.50) | CTSKCTSSSCN9ASYKATM | |
| SCHEMBL19573703 | 0.86 | CTSK (0.50) | CTSKCTSSSCN9ASYKATM | |
| SCHEMBL18409014 | 0.86 | CTSK (0.50) | CTSKCTSSSCN9ASYKATM | |
| SCHEMBL19222886 | 0.77 | MME (0.60) | CTSKCTSSSCN9AMMP2MMP3 | |
| SCHEMBL22651626 | 0.77 | CTSK (0.63) | CTSKCTSSPPARAPPARGBCL2 | |
| SCHEMBL344068 | 0.77 | CTSK (0.63) | CTSKCTSSPPARAPPARGBCL2 | |
| SCHEMBL19605638 | 0.77 | CTSK (0.63) | CTSKCTSSPPARAPPARGBCL2 | |
| SCHEMBL1231410 | 0.76 | MME (0.54) | CTSKCTSSSCN9AATM | |
| SCHEMBL21572792 | 0.76 | MME (0.54) | CTSKCTSSSCN9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-9682052-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | CTSK 123/4885CTSS 86/4885MMP12 686/4885 |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CTSK 178/4885CTSS 117/4885MMP12 1089/4885 |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CTSK 123/4885CTSS 86/4885MMP12 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.